MergerApr 23, 2026, 04:26 PM
BioMarin-Amicus Merger Receives French FDI Clearance, Set to Close April 27
AI Summary
BioMarin Pharmaceutical Inc. announced that its merger with Amicus Therapeutics, Inc. has received clearance under French foreign direct investment screening procedures. This French FDI Clearance satisfies the final pre-closing condition for the merger, paving the way for the transaction. The acquisition is now expected to close on April 27, 2026, at which point Amicus will become a wholly owned subsidiary of BioMarin.
Key Highlights
- French FDI Clearance granted for BioMarin-Amicus merger.
- Clearance satisfies the final pre-closing condition for the merger.
- Merger is now expected to close on April 27, 2026.
- Amicus Therapeutics will become a wholly owned subsidiary of BioMarin.